Table 1.
Characteristics of the study population.
Table 2.
Beta regression analysis of the proportion of CysC proteoforms among patients’ groups.
The table shows the proportion (%, 95% CI) of total CysC and the explained variance by patients’ group (R2).
Table 3.
Beta regression on the association of prescribed drugs with the proportion of CysC proteoforms.
Fig 1.
The association between total cystatin C and eGFR calculated based on creatinine, cystatin C, or both in CKD patients (CKD 3–5 and transplant).
The individual data points are colored according to patient group, and the overall association is superimposed as a smoothed spline (95% CI).
Fig 2.
Bland-Altman plot on the differences between eGFRcysc and eGFRcrea in CKD patients (CKD 3–5 and transplant).
The superimposed regression line indicates the association between the differences and the mean value.
Fig 3.
Pearson correlation between the proportion of the different proteoforms and the difference in eGFR based on creatinine and cystatin C (eGFRcysc–eGFRcrea) in CKD patients (CKD 3–5 and transplant).
The individual data points are colored according to patient group.
Fig 4.
Dirichlet regression on the association of eGFR with proteoforms of cystatin C in CKD patients (n = 102, CKD 3–5 and transplant).
The dots show the observed data while the lines show the fitted data. The model shows the linear estimates with adjustment for patients’ group, ATC-H02, ATC-L04 and CRP.